Peripheral Blood T-lymphocyte Phenotypes in Mother-Child Pairs Stratified by the Maternal HPV Status: Persistent HPV16 vs. HPV-Negative: A Case-Control Study
暂无分享,去创建一个
S. Grénman | S. Syrjänen | K. Syrjänen | K. Louvanto | A. Paaso | Hanna-Mari Koskimaa | Helmi Suominen
[1] M. Pawlita,et al. Maternal HPV-antibodies and seroconversion to HPV in children during the first 3 years of life , 2022, Scientific Reports.
[2] M. Neagu,et al. Assessment of Immune Cell Populations in Tumor Tissue and Peripheral Blood Samples from Head and Neck Squamous Cell Carcinoma Patients , 2021, Analytical cellular pathology.
[3] M. G. Bonecini-Almeida,et al. A prognostic value of CD45RA+, CD45RO+, CCL20+ and CCR6+ expressing cells as ‘immunoscore’ to predict cervical cancer induced by HPV , 2021, Scientific Reports.
[4] S. Grénman,et al. Oral Human Papillomavirus Infection in Children during the First 6 Years of Life, Finland , 2021, Emerging infectious diseases.
[5] S. H. van der Burg,et al. Interferon‐γ and IL‐5 associated cell‐mediated immune responses to HPV16 E2 and E6 distinguish between persistent oral HPV16 infections and noninfected mucosa , 2021, Clinical and experimental dental research.
[6] M. Stanley,et al. Infiltrating T-cell markers in cervical carcinogenesis: a systematic review and meta-analysis , 2020, British Journal of Cancer.
[7] M. Zvâncă,et al. Non-sexual HPV transmission and role of vaccination for a better future (Review). , 2020, Experimental and therapeutic medicine.
[8] M. Moneer,et al. Frequency of CD4+ regulatory T cells, CD8+ T cells, and human papilloma virus infection in Egyptian Women with breast cancer , 2020, International journal of immunopathology and pharmacology.
[9] Renu Yadav,et al. Immunology of HPV-mediated cervical cancer: current understanding , 2020, International reviews of immunology.
[10] J. Cuzick,et al. Role of HPV Genotype, Multiple Infections, and Viral Load on the Risk of High-Grade Cervical Neoplasia , 2019, Cancer Epidemiology, Biomarkers & Prevention.
[11] E. Wherry,et al. CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer. , 2019, Annual review of immunology.
[12] Dong Kyu Lee,et al. What is the proper way to apply the multiple comparison test? , 2018, Korean journal of anesthesiology.
[13] R. Barnabas,et al. HIV-positive women have higher risk of human papilloma virus infection, precancerous lesions, and cervical cancer , 2018, AIDS.
[14] P. Stern,et al. Opportunities and challenges for human papillomavirus vaccination in cancer , 2018, Nature Reviews Cancer.
[15] A. Kamphorst,et al. CD8 T Cell Exhaustion in Chronic Infection and Cancer: Opportunities for Interventions. , 2018, Annual review of medicine.
[16] A. Stensballe,et al. Induction of a Regulatory Phenotype in CD3+ CD4+ HLA-DR+ T Cells after Allogeneic Mixed Lymphocyte Culture; Indications of Both Contact-Dependent and -Independent Activation , 2017, International journal of molecular sciences.
[17] A. Nyitray,et al. Penises not required: a systematic review of the potential for human papillomavirus horizontal transmission that is non-sexual or does not include penile penetration. , 2016, Sexual health.
[18] L. Montaner,et al. High-risk oncogenic HPV genotype infection associates with increased immune activation and T cell exhaustion in ART-suppressed HIV-1-infected women , 2016, Oncoimmunology.
[19] Sing Sing Way,et al. Regulatory T cell memory , 2015, Nature Reviews Immunology.
[20] M. Grimm,et al. Immunophenotyping of patients with oral squamous cell carcinoma in peripheral blood and associated tumor tissue , 2016, Tumor Biology.
[21] S. H. van der Burg,et al. Human papillomavirus 16-specific cell-mediated immunity in children born to mothers with incident cervical intraepithelial neoplasia (CIN) and to those constantly HPV negative , 2015, Journal of Translational Medicine.
[22] S. H. van der Burg,et al. Cell mediated immunity against HPV16 E2, E6 and E7 peptides in women with incident CIN and in constantly HPV-negative women followed-up for 10-years , 2015, Journal of Translational Medicine.
[23] S. H. van der Burg,et al. Human papillomavirus 16 E2-, E6- and E7-specific T-cell responses in children and their mothers who developed incident cervical intraepithelial neoplasia during a 14-year follow-up of the Finnish Family HPV cohort , 2014, Journal of Translational Medicine.
[24] M. Kee,et al. Distribution of maternal and infant human papillomavirus: risk factors associated with vertical transmission. , 2013, European journal of obstetrics, gynecology, and reproductive biology.
[25] S. Weyers,et al. Transmission of carcinogenic human papillomavirus types from mother to child: a meta-analysis of published studies , 2013, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.
[26] Yali Hu,et al. Survey of human papillomavirus types and their vertical transmission in pregnant women , 2013, BMC Infectious Diseases.
[27] M. Shipkova,et al. Surface markers of lymphocyte activation and markers of cell proliferation. , 2012, Clinica chimica acta; international journal of clinical chemistry.
[28] M. Pawlita,et al. Human papillomavirus genotypes present in the oral mucosa of newborns and their concordance with maternal cervical human papillomavirus genotypes. , 2012, The Journal of pediatrics.
[29] M. Pawlita,et al. Lack of type-specific concordance between human papillomavirus (HPV) serology and HPV DNA detection in the uterine cervix and oral mucosa. , 2011, The Journal of general virology.
[30] Xin Chen,et al. The phenotypic and functional consequences of tumour necrosis factor receptor type 2 expression on CD4+ FoxP3+ regulatory T cells , 2011, Immunology.
[31] M. Schiffman,et al. Alterations of T‐cell surface markers in older women with persistent human papillomavirus infection , 2011, International journal of cancer.
[32] S. H. van der Burg,et al. Induction of Tumor-Specific CD4+ and CD8+ T-Cell Immunity in Cervical Cancer Patients by a Human Papillomavirus Type 16 E6 and E7 Long Peptides Vaccine , 2008, Clinical Cancer Research.
[33] E. Schuuring,et al. Frequencies and role of regulatory T cells in patients with (pre)malignant cervical neoplasia , 2007, Clinical and experimental immunology.
[34] Clare Baecher-Allan,et al. MHC Class II Expression Identifies Functionally Distinct Human Regulatory T Cells1 , 2006, The Journal of Immunology.
[35] Peter J. F. Snijders,et al. Bead-Based Multiplex Genotyping of Human Papillomaviruses , 2006, Journal of Clinical Microbiology.
[36] R. Lechler,et al. Acquisition of HLA‐DR and Costimulatory Molecules by T Cells from Allogeneic Antigen Presenting Cells , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[37] N. Kiviat,et al. Development and duration of human papillomavirus lesions, after initial infection. , 2005, The Journal of infectious diseases.
[38] G. Tortolero-Luna,et al. Human papillomavirus infection: biology, epidemiology, and prevention , 2005, International Journal of Gynecologic Cancer.
[39] S. Grénman,et al. Transmission of High-Risk Human Papillomavirus (HPV) between Parents and Infant: a Prospective Study of HPV in Families in Finland , 2005, Journal of Clinical Microbiology.
[40] J. M. van der Hulst,et al. Human Papillomavirus Type 16-Positive Cervical Cancer Is Associated with Impaired CD4+ T-Cell Immunity against Early Antigens E2 and E6 , 2004, Cancer Research.
[41] P. J. van den Elsen,et al. Function and regulation of MHC class II molecules in T-lymphocytes: of mice and men. , 2004, Human immunology.
[42] Antonio Lanzavecchia,et al. Central memory and effector memory T cell subsets: function, generation, and maintenance. , 2004, Annual review of immunology.
[43] R. Lechler,et al. Antigen presentation by mouse CD4+ T cells involving acquired MHC class II:peptide complexes: another mechanism to limit clonal expansion? , 2003, Blood.
[44] J. M. van der Hulst,et al. Frequent display of human papillomavirus type 16 E6-specific memory t-Helper cells in the healthy population as witness of previous viral encounter. , 2003, Cancer research.
[45] R. Seufert,et al. CD8+CD45RA+CD27-CD28-T-cell subset in PBL of cervical cancer patients representing CD8+T-cells being able to recognize cervical cancer associated antigens provided by HPV 16 E7 , 2002, Zentralblatt fur Gynakologie.
[46] E. Wang,et al. Analysis of CD4+ T-Cell Responses to Human Papillomavirus (HPV) Type 11 L1 in Healthy Adults Reveals a High Degree of Responsiveness and Cross-Reactivity with Other HPV Types , 2002, Journal of Virology.
[47] A. Rickinson,et al. Epitope-specific Evolution of Human CD8+ T Cell Responses from Primary to Persistent Phases of Epstein-Barr Virus Infection , 2002, The Journal of experimental medicine.
[48] P. Coursaget,et al. Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia. I. Differential T-helper and IgG responses in relation to HPV infection and disease outcome. , 1999, The Journal of general virology.
[49] C. Meijer,et al. Differential T helper cell responses to human papillomavirus type 16 E7 related to viral clearance or persistence in patients with cervical neoplasia: a longitudinal study. , 1998, Cancer research.
[50] T. Wyss-Coray,et al. T cells as antigen-presenting cells. , 1994, Immunology today.